{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T08:49:52Z","timestamp":1777538992356,"version":"3.51.4"},"reference-count":50,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2018,4,1]],"date-time":"2018-04-01T00:00:00Z","timestamp":1522540800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2018,4,1]],"date-time":"2018-04-01T00:00:00Z","timestamp":1522540800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["jpet.aspetjournals.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The Journal of Pharmacology and Experimental Therapeutics"],"published-print":{"date-parts":[[2018,4]]},"DOI":"10.1124\/jpet.117.246439","type":"journal-article","created":{"date-parts":[[2018,1,12]],"date-time":"2018-01-12T18:16:04Z","timestamp":1515780964000},"page":"37-47","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":24,"title":["Application of Receptor Theory to the Design and Use of Fixed-Proportion Mu-Opioid Agonist and Antagonist Mixtures in Rhesus Monkeys"],"prefix":"10.1016","volume":"365","author":[{"given":"Jeremy C","family":"Cornelissen","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Samuel","family":"Obeng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kenner C","family":"Rice","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yan","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S. Stevens","family":"Negus","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Matthew L","family":"Banks","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1124\/jpet.117.246439_bib1","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1016\/S0022-3565(24)29358-7","article-title":"Stimulation of guanosine-5\u2032-O-(3-[35S]thio)triphosphate binding in digitonin-permeabilized C6 rat glioma cells: evidence for an organized association of \u03bc-opioid receptors and G protein","volume":"298","author":"Alt","year":"2001","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1124\/jpet.117.246439_bib2","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1016\/j.pbb.2010.07.019","article-title":"Selective enhancement of fentanyl-induced antinociception by the delta agonist SNC162 but not by ketamine in rhesus monkeys: further evidence supportive of delta agonists as candidate adjuncts to mu opioid analgesics","volume":"97","author":"Banks","year":"2010","journal-title":"Pharmacol Biochem Behav"},{"key":"10.1124\/jpet.117.246439_bib3","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1124\/jpet.110.169276","article-title":"Antinociceptive interactions between mu-opioid receptor agonists and the serotonin uptake inhibitor clomipramine in rhesus monkeys: role of mu agonist efficacy","volume":"335","author":"Banks","year":"2010","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1124\/jpet.117.246439_bib4","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1007\/s002130000567","article-title":"Agonist efficacy, drug dependence, and medications development: preclinical evaluation of opioid, dopaminergic, and GABAA-ergic ligands","volume":"153","author":"Bergman","year":"2000","journal-title":"Psychopharmacology (Berl)"},{"key":"10.1124\/jpet.117.246439_bib5","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1124\/jpet.302.1.264","article-title":"Antagonism of the antinociceptive and discriminative stimulus effects of heroin and morphine by 3-methoxynaltrexone and naltrexone in rhesus monkeys","volume":"302","author":"Bowen","year":"2002","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1124\/jpet.117.246439_bib6","doi-asserted-by":"crossref","first-page":"1262","DOI":"10.1097\/ALN.0000000000000170","article-title":"Buprenorphine-naloxone therapy in pain management","volume":"120","author":"Chen","year":"2014","journal-title":"Anesthesiology"},{"key":"10.1124\/jpet.117.246439_bib7","doi-asserted-by":"crossref","first-page":"E5511","DOI":"10.1073\/pnas.1605295113","article-title":"A novel orvinol analog, BU08028, as a safe opioid analgesic without abuse liability in primates","volume":"113","author":"Ding","year":"2016","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1124\/jpet.117.246439_bib8","doi-asserted-by":"crossref","first-page":"1121","DOI":"10.1016\/S0022-3565(25)20761-3","article-title":"Characterization of opioid agonist efficacy in a C6 glioma cell line expressing the mu opioid receptor","volume":"278","author":"Emmerson","year":"1996","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1124\/jpet.117.246439_bib9","doi-asserted-by":"crossref","first-page":"1630","DOI":"10.1016\/S0022-3565(25)24051-4","article-title":"Binding affinity and selectivity of opioids at mu, delta and kappa receptors in monkey brain membranes","volume":"271","author":"Emmerson","year":"1994","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1124\/jpet.117.246439_bib10","doi-asserted-by":"crossref","first-page":"3811","DOI":"10.2147\/DDDT.S73561","article-title":"Developments in managing severe chronic pain: role of oxycodone-naloxone extended release","volume":"9","author":"Fanelli","year":"2015","journal-title":"Drug Des Devel Ther"},{"key":"10.1124\/jpet.117.246439_bib11","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1002\/j.1552-4604.1967.tb00029.x","article-title":"Clinical investigation of the analgesic potency and respiratory depressant activity of fentanyl, a new narcotic analgesic","volume":"7","author":"Finch","year":"1967","journal-title":"J Clin Pharmacol J New Drugs"},{"key":"10.1124\/jpet.117.246439_bib12","doi-asserted-by":"crossref","first-page":"992","DOI":"10.1016\/S0022-3565(25)22568-X","article-title":"Behavioral effects of 6-methylene naltrexone (nalmefene) in rhesus monkeys","volume":"270","author":"France","year":"1994","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1124\/jpet.117.246439_bib13","series-title":"Advances in Drug Research","first-page":"21","article-title":"The use of \u03b2-haloalkylamines in the differentiation of receptors and in the determination of dissociation constants of receptor-agonist complexes","author":"Furchgott","year":"1966"},{"key":"10.1124\/jpet.117.246439_bib14","doi-asserted-by":"crossref","first-page":"1346","DOI":"10.1016\/S0022-3565(25)12191-5","article-title":"Antinociceptive effects of cocaine\/opioid combinations in rhesus monkeys","volume":"275","author":"Gatch","year":"1995","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1124\/jpet.117.246439_bib15","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1016\/S0022-3565(25)23877-0","article-title":"Antinociceptive and respiratory effects of nalbuphine in rhesus monkeys","volume":"271","author":"Gerak","year":"1994","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1124\/jpet.117.246439_bib16","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1007\/s00213-007-0787-y","article-title":"Time-dependent decreases in apparent pA2 values for naltrexone studied in combination with morphine in rhesus monkeys","volume":"193","author":"Gerak","year":"2007","journal-title":"Psychopharmacology (Berl)"},{"key":"10.1124\/jpet.117.246439_bib17","doi-asserted-by":"crossref","first-page":"1.","DOI":"10.1186\/1471-2210-3-1","article-title":"Activity of opioid ligands in cells expressing cloned mu opioid receptors","volume":"3","author":"Gharagozlou","year":"2003","journal-title":"BMC Pharmacol"},{"key":"10.1124\/jpet.117.246439_bib18","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1124\/jpet.116.233163","article-title":"Stratification of cannabinoid 1 receptor (CB1R) agonist efficacy: manipulation of CB1R density through use of transgenic mice reveals congruence between in vivo and in vitro assays","volume":"359","author":"Grim","year":"2016","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1124\/jpet.117.246439_bib19","series-title":"Pharmacologic Analysis of Drug Receptor Interaction","author":"Kenakin","year":"1993"},{"key":"10.1124\/jpet.117.246439_bib20","series-title":"Pharmacology in Drug Discovery","author":"Kenakin","year":"2012"},{"key":"10.1124\/jpet.117.246439_bib21","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1016\/S0014-2999(00)00039-X","article-title":"Buprenorphine and methoclocinnamox: agonist and antagonist effects on respiratory function in rhesus monkeys","volume":"391","author":"Kishioka","year":"2000","journal-title":"Eur J Pharmacol"},{"key":"10.1124\/jpet.117.246439_bib22","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1016\/S0022-3565(24)37416-6","article-title":"Differentiation of kappa opioid agonist-induced antinociception by naltrexone apparent pA2 analysis in rhesus monkeys","volume":"285","author":"Ko","year":"1998","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1124\/jpet.117.246439_bib23","doi-asserted-by":"crossref","first-page":"1416","DOI":"10.1021\/jm801272c","article-title":"Design, synthesis, and biological evaluation of 6\u03b1- and 6\u03b2-N-heterocyclic substituted naltrexamine derivatives as \u03bc opioid receptor selective antagonists","volume":"52","author":"Li","year":"2009","journal-title":"J Med Chem"},{"key":"10.1124\/jpet.117.246439_bib24","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1124\/jpet.114.216648","article-title":"Impact of efficacy at the \u03bc-opioid receptor on antinociceptive effects of combinations of \u03bc-opioid receptor agonists and cannabinoid receptor agonists","volume":"351","author":"Maguire","year":"2014","journal-title":"J Pharmacol Exp Ther"},{"issue":"2","key":"10.1124\/jpet.117.246439_bib25","doi-asserted-by":"crossref","first-page":"S29","DOI":"10.1016\/S0376-8716(03)00057-7","article-title":"Clinical and pharmacological evaluation of buprenorphine and naloxone combinations: why the 4:1 ratio for treatment?","volume":"70","author":"Mendelson","year":"2003","journal-title":"Drug Alcohol Depend"},{"key":"10.1124\/jpet.117.246439_bib26","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1016\/S0022-3565(25)20725-X","article-title":"Kappa-opioid receptor-mediated antinociception in the rat. I. Comparative actions of mu- and kappa-opioids against noxious thermal, pressure and electrical stimuli","volume":"251","author":"Millan","year":"1989","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1124\/jpet.117.246439_bib27","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1254\/jphs.09139FP","article-title":"Morphine, oxycodone, and fentanyl exhibit different analgesic profiles in mouse pain models","volume":"111","author":"Minami","year":"2009","journal-title":"J Pharmacol Sci"},{"key":"10.1124\/jpet.117.246439_bib50","series-title":"Guide for the care and use of laboratory animals","year":"2011"},{"key":"10.1124\/jpet.117.246439_bib28","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1097\/00008877-200211000-00005","article-title":"Delta opioid antagonist effects of buprenorphine in rhesus monkeys","volume":"13","author":"Negus","year":"2002","journal-title":"Behav Pharmacol"},{"key":"10.1124\/jpet.117.246439_bib29","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/S0376-8716(02)00331-9","article-title":"Effects of heroin and its metabolites on schedule-controlled responding and thermal nociception in rhesus monkeys: sensitivity to antagonism by quadazocine, naltrindole and \u03b2-funaltrexamine","volume":"70","author":"Negus","year":"2003","journal-title":"Drug Alcohol Depend"},{"key":"10.1124\/jpet.117.246439_bib30","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1016\/S0022-3565(25)39549-2","article-title":"Effects of opioid agonists selective for mu, kappa and delta opioid receptors on schedule-controlled responding in rhesus monkeys: antagonism by quadazocine","volume":"267","author":"Negus","year":"1993","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1124\/jpet.117.246439_bib31","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1213\/00000539-199102000-00015","article-title":"Cardiovascular, respiratory, and analgesic effects of fentanyl in unanesthetized rhesus monkeys","volume":"72","author":"Nussmeier","year":"1991","journal-title":"Anesth Analg"},{"key":"10.1124\/jpet.117.246439_bib32","doi-asserted-by":"crossref","first-page":"67","DOI":"10.3109\/15360288.2014.1003680","article-title":"The attractiveness of opposites: agonists and antagonists","volume":"29","author":"O\u2019Brien","year":"2015","journal-title":"J Pain Palliat Care Pharmacother"},{"key":"10.1124\/jpet.117.246439_bib33","doi-asserted-by":"crossref","first-page":"1197","DOI":"10.1016\/S0022-3565(24)37502-0","article-title":"Clocinnamox antagonism of the antinociceptive effects of mu opioids in squirrel monkeys","volume":"285","author":"Pitts","year":"1998","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1124\/jpet.117.246439_bib34","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1007\/s002130000427","article-title":"Cocaine-like discriminative stimulus effects of heroin in squirrel monkeys: role of active metabolites and opioid receptor mechanisms","volume":"150","author":"Rowlett","year":"2000","journal-title":"Psychopharmacology (Berl)"},{"key":"10.1124\/jpet.117.246439_bib35","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1111\/j.1474-8673.1982.tb00520.x","article-title":"Review important concepts of receptor theory","volume":"2","author":"Ruffolo","year":"1982","journal-title":"J Auton Pharmacol"},{"key":"10.1124\/jpet.117.246439_bib36","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1016\/S0022-3565(24)37462-2","article-title":"Signal transduction correlates of mu opioid agonist intrinsic efficacy: receptor-stimulated [35S]GTP\u03b3S binding in mMOR-CHO cells and rat thalamus","volume":"285","author":"Selley","year":"1998","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1124\/jpet.117.246439_bib37","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1124\/jpet.116.232421","article-title":"Antinociceptive interactions between the imidazoline I2 receptor agonist 2-BFI and opioids in rats: role of efficacy at the \u03bc-opioid receptor","volume":"357","author":"Siemian","year":"2016","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1124\/jpet.117.246439_bib38","doi-asserted-by":"crossref","first-page":"1054","DOI":"10.1124\/jpet.103.056515","article-title":"Opioid interactions in rhesus monkeys: effects of \u03b4 + \u03bc and \u03b4 + \u03ba agonists on schedule-controlled responding and thermal nociception","volume":"307","author":"Stevenson","year":"2003","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1124\/jpet.117.246439_bib39","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1124\/jpet.103.058602","article-title":"Activation of G-proteins by morphine and codeine congeners: insights to the relevance of O- and N-demethylated metabolites at \u03bc- and \u03b4-opioid receptors","volume":"308","author":"Thompson","year":"2004","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1124\/jpet.117.246439_bib40","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1016\/S0022-3565(25)39351-1","article-title":"Opioid thermal antinociception in rhesus monkeys: receptor mechanisms and temperature dependency","volume":"267","author":"Walker","year":"1993","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1124\/jpet.117.246439_bib41","doi-asserted-by":"crossref","first-page":"959","DOI":"10.1016\/S0022-3565(25)23869-1","article-title":"In vivo apparent pA2 analysis for naltrexone antagonism of discriminative stimulus and analgesic effects of opiate agonists in rats","volume":"271","author":"Walker","year":"1994","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1124\/jpet.117.246439_bib42","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1124\/jpet.302.1.101","article-title":"Clocinnamox distinguishes opioid agonists according to relative efficacy in normal and morphine-treated rats trained to discriminate morphine","volume":"302","author":"Walker","year":"2002","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1124\/jpet.117.246439_bib43","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1016\/S0022-3565(25)09651-X","article-title":"Buprenorphine antagonism of mu opioids in the rhesus monkey tail-withdrawal procedure","volume":"273","author":"Walker","year":"1995","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1124\/jpet.117.246439_bib44","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1007\/s002130050534","article-title":"In vivo apparent affinity and efficacy estimates for mu opiates in a rat tail-withdrawal assay","volume":"136","author":"Walker","year":"1998","journal-title":"Psychopharmacology (Berl)"},{"key":"10.1124\/jpet.117.246439_bib45","doi-asserted-by":"crossref","first-page":"1701","DOI":"10.1016\/j.bmc.2015.02.055","article-title":"Design, syntheses, and pharmacological characterization of 17-cyclopropylmethyl-3,14\u03b2-dihydroxy-4,5\u03b1-epoxy-6\u03b1-(isoquinoline-3\u2032-carboxamido)morphinan analogues as opioid receptor ligands","volume":"23","author":"Yuan","year":"2015","journal-title":"Bioorg Med Chem"},{"key":"10.1124\/jpet.117.246439_bib46","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/S0022-3565(25)38710-0","article-title":"In vivo determination of mu opioid receptor turnover in rhesus monkeys after irreversible blockade with clocinnamox","volume":"269","author":"Zernig","year":"1994","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1124\/jpet.117.246439_bib47","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1007\/s002130050185","article-title":"Clocinnamox inhibits the intravenous self-administration of opioid agonists in rhesus monkeys: comparison with effects on opioid agonist-mediated antinociception","volume":"129","author":"Zernig","year":"1997","journal-title":"Psychopharmacology (Berl)"},{"key":"10.1124\/jpet.117.246439_bib48","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1016\/j.ejphar.2014.04.041","article-title":"Behavioral and cellular pharmacology characterization of 17-cyclopropylmethyl-3,14\u03b2-dihydroxy-4,5\u03b1-epoxy-6\u03b1-(isoquinoline-3\u2032-carboxamido)morphinan (NAQ) as a mu opioid receptor selective ligand","volume":"736","author":"Zhang","year":"2014","journal-title":"Eur J Pharmacol"},{"key":"10.1124\/jpet.117.246439_bib49","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1016\/S0022-5347(25)00270-8","article-title":"Use of beta-funaltrexamine to determine mu opioid receptor involvement in the analgesic activity of various opioid ligands","volume":"241","author":"Zimmerman","year":"1987","journal-title":"J Pharmacol Exp Ther"}],"container-title":["The Journal of Pharmacology and Experimental Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022356524268142?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022356524268142?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1124\/jpet.117.246439","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,19]],"date-time":"2025-02-19T20:05:38Z","timestamp":1739995538000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0022356524268142"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,4]]},"references-count":50,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2018,4]]}},"alternative-id":["S0022356524268142"],"URL":"https:\/\/doi.org\/10.1124\/jpet.117.246439","relation":{},"ISSN":["0022-3565"],"issn-type":[{"value":"0022-3565","type":"print"}],"subject":[],"published":{"date-parts":[[2018,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Application of Receptor Theory to the Design and Use of Fixed-Proportion Mu-Opioid Agonist and Antagonist Mixtures in Rhesus Monkeys","name":"articletitle","label":"Article Title"},{"value":"The Journal of Pharmacology and Experimental Therapeutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1124\/jpet.117.246439","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"U.S. Government work not protected by U.S. copyright","name":"copyright","label":"Copyright"}]}}